文献速递胸部肿瘤消化系统肿瘤

雷莫芦单抗联合度伐利尤单抗治疗经治晚期NSCLC、胃/胃食管结合部腺癌或肝细胞癌:开放标签Ia/b期研究(JVDJ)

Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
PubMed 文献 · Eur J Cancer · 2020-08-19

该多中心单臂Ia/b期研究评估雷莫芦单抗联合度伐利尤单抗在经治晚期NSCLC、胃/胃食管结合部腺癌或肝细胞癌患者中的安全性和初步疗效。结果显示联合方案安全性可控,在各队列中均显示抗肿瘤活性,尤其在PD-L1高表达患者中生存期更长。

要点

  • 雷莫芦单抗联合度伐利尤单抗在经治晚期NSCLC、胃/GEJ腺癌和HCC中安全性可控。
  • 客观缓解率NSCLC和HCC均为11%,胃/GEJ为21%。
  • PD-L1高表达患者生存期更长。

核心结论

  • 雷莫芦单抗联合度伐利尤单抗安全性可控,在各队列中均显示抗肿瘤活性,尤其在PD-L1高表达患者中。

研究设计与样本

  • 25中心、Ia/b期单臂、非随机、多队列研究,纳入经治晚期/转移性NSCLC、胃/GEJ腺癌或HCC患者,ECOG PS 0-1,无既往雷莫芦单抗或免疫治疗,任何PD-L1状态。

主要发现

  • NSCLC队列28例,胃/GEJ队列29例,HCC队列28例。
  • ≥3级治疗相关不良事件发生率分别为32.1%、37.9%和42.9%。
  • 最常见不良事件分别为疲劳(35.7%)、高血压(34.5%)和腹泻(28.6%)。
  • 2例患者因不良事件死亡,其中1例为治疗相关(急性肝炎,HCC队列)。
  • 客观缓解率NSCLC和HCC均为11%,胃/GEJ为21%。

关键数值与推荐

  • NSCLC给药方案:雷莫芦单抗10 mg/kg联合度伐利尤单抗1125 mg静脉注射每3周一次。
  • 胃/GEJ和HCC给药方案:雷莫芦单抗8 mg/kg联合度伐利尤单抗750 mg每2周一次。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging evidence supports combining immune checkpoint inhibitors (ICIs) with conventional or targeted therapies to enhance ICI antitumour activity and broaden the spectrum of patients who respond to ICIs. Here, we present the safety and preliminary efficacy of ramucirumab, an anti-VEGFR2 IgG1, plus durvalumab, an anti-PD-L1 IgG1, in previously treated patients with advanced non-small-cell lung cancer (NSCLC), gastric/gastro-oesophageal junction adenocarcinoma (gastric/GEJ), or hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A 25-centre, phase Ia/b single-arm, non-randomised, multi-cohort study was undertaken in patients with advanced/metastatic disease, Eastern Cooperative Oncology Group performance status, 0-1, progression on prior therapy, no prior ramucirumab or immunotherapy and any PD-L1 status. Patients received ramucirumab (10 mg/kg) plus durvalumab (1125 mg) intravenously Q3W (NSCLC), or ramucirumab (8 mg/kg) plus durvalumab (750 mg) Q2W (gastric/GEJ, HCC). RESULTS: Phase Ia treatment was found safe for phase Ib expansion; final enrolment was NSCLC (n = 28), gastric/GEJ (n = 29), HCC (n = 28). Grade ≥3 treatment-related adverse events occurred in 32.1%, 37.9% and 42.9% of patients, respectively. The most common were fatigue (35.7%), hypertension (34.5%) and diarrhoea (28.6%), respectively. Two patients died owing to an adverse event; one was treatment-related (hepatitis acute, HCC cohort). Objective response rate was 11% for NSCLC and HCC and 21% for gastric/GEJ. Median progression-free survival and overall survival were, respectively, 2.7 and 11 months in NSCLC; 2.6 and 12.4 months in gastric/GEJ; 4.4 and 10.7 months in HCC, with more prolonged survival in patients with high PD-L1 expression. CONCLUSION: Ramucirumab/durvalumab exhibited manageable safety. The combination showed antitumour activity in all cohorts, particularly in patients with high PD-L1 expression.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020. PMID: 32827847. doi:10.1016/j.ejca.2020.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。